A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.

Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T

The Journal of clinical endocrinology and metabolism1 Dec 2001Cited by 45 (Europe PMC)

PMID11739429DOI10.1210/jcem.86.12.8119PepBankPUB-11739429

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory metastatic prostate cancer, triptorelin plus dexamethasone and lanreotide produced durable objective responses in 90.9% of patients.
In plain wordsIn refractory prostate cancer, 90.9% of patients responded to triptorelin plus dexamethasone and lanreotide.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableObjective clinical response
Study
n = 11
Outcome group
Tumor growth · Cancer
Measurements
Objective response
90.9%
combination therapy
Source sentences
Summary
Ten of 11 stage D3 patients [90.9% of patients; 95% confidence interval (CI), 58.7-99.8%] had durable objective clinical responses (including > or = 50% prostate-specific antigen decline in 8 patients, 72.7%; 95% CI, 39-94%).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942901
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, 72.7% of patients receiving triptorelin plus dexamethasone and lanreotide had at least a 50% PSA decline.
In plain wordsIn refractory prostate cancer, 72.7% of patients receiving the three-drug regimen had at least a 50% PSA decline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePSA decline of at least 50%
Study
n = 11
Outcome group
Tumor growth · Cancer
Measurements
PSA response
72.7%
combination therapy
Source sentences
Summary
Ten of 11 stage D3 patients [90.9% of patients; 95% confidence interval (CI), 58.7-99.8%] had durable objective clinical responses (including > or = 50% prostate-specific antigen decline in 8 patients, 72.7%; 95% CI, 39-94%).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942902
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, all patients reported improved bone pain during triptorelin plus dexamethasone and lanreotide treatment.
In plain wordsIn refractory prostate cancer, all patients reported less bone pain during the three-drug treatment than before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone pain
Study
n = 11
Outcome group
Pain · Cancer
Measurements
Median duration of bone pain improvement
13 months
combination therapy
Source sentences
Summary
All patients reported significant and durable improvement of bone pain (for a median duration of 13 months; 95% CI, 12-14 months; range, 6-22 months) and performance status (median duration, 19 months; 95% CI, 13-25 months; range, 7-22 months) without major treatment-related side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942903
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, all patients reported improved performance status during triptorelin plus dexamethasone and lanreotide treatment.
In plain wordsIn refractory prostate cancer, all patients reported better physical function during the three-drug treatment than before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePerformance status
Study
n = 11
Outcome group
Exercise and physical function · Cancer
Measurements
Median duration of performance status improvement
19 months
combination therapy
Source sentences
Summary
All patients reported significant and durable improvement of bone pain (for a median duration of 13 months; 95% CI, 12-14 months; range, 6-22 months) and performance status (median duration, 19 months; 95% CI, 13-25 months; range, 7-22 months) without major treatment-related side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942904
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
In refractory prostate cancer, the triptorelin, dexamethasone and lanreotide regimen produced no major treatment-related side effects.
In plain wordsIn refractory prostate cancer, the three-drug regimen produced no major treatment-related side effects.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeMajor treatment-related side effects
Study
n = 11
Outcome group
Adverse events · Cancer
Source sentences
Summary
All patients reported significant and durable improvement of bone pain (for a median duration of 13 months; 95% CI, 12-14 months; range, 6-22 months) and performance status (median duration, 19 months; 95% CI, 13-25 months; range, 7-22 months) without major treatment-related side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942905
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, median progression-free survival during triptorelin plus dexamethasone and lanreotide treatment was 7 months.
In plain wordsIn refractory prostate cancer, median survival without progression during the three-drug regimen was 7 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableProgression-free survival
Study
n = 11
Outcome group
Tumor growth · Cancer
Measurements
Median progression-free survival
7 months
combination therapy
Source sentences
Summary
The median progression-free survival was 7 months (95% CI, 4-10 months; range, 3-17 months), and the median overall survival was 18 months (95% CI, 16-20 months; range, 7-22 months).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942906
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, median overall survival during triptorelin plus dexamethasone and lanreotide treatment was 18 months.
In plain wordsIn refractory prostate cancer, median survival during the three-drug regimen was 18 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOverall survival
Study
n = 11
Outcome group
Mortality · Cancer
Measurements
Median overall survival
18 months
combination therapy
Source sentences
Summary
The median progression-free survival was 7 months (95% CI, 4-10 months; range, 3-17 months), and the median overall survival was 18 months (95% CI, 16-20 months; range, 7-22 months).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942907
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
In patients receiving triptorelin plus dexamethasone and lanreotide, six deaths occurred, five from disease progression.
In plain wordsIn patients receiving the three-drug regimen, six died, including five from cancer progression.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableDeaths
Study
n = 11
Outcome group
Mortality · Cancer
Measurements
Total deaths
6 patients
combination therapy
Deaths from disease progression
5 patients
combination therapy
Source sentences
Summary
Five of six total deaths occurred secondary to disease progression.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942908
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, testosterone remained below 3 nmol/liter throughout triptorelin plus dexamethasone and lanreotide therapy, including relapse.
In plain wordsIn refractory prostate cancer, testosterone stayed at castration levels throughout the three-drug regimen, including relapse.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTestosterone suppression
Study
n = 11
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Testosterone level
< 3 nmol/liter
baseline through relapse
Source sentences
Summary
T levels remained suppressed within castration levels (<3 nmol/liter, at baseline and throughout therapy, including relapse).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942911
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, serum IGF-I decreased by 60% at response to triptorelin plus dexamethasone and lanreotide.
In plain wordsIn refractory prostate cancer, natural IGF-I levels decreased by 60% from baseline at response to the three-drug regimen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum IGF-I
Study
n: not reported in source
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
IGF-I reduction
60%
response versus baseline
Source sentences
Summary
We observed a statistically significant (P = 0.018) reduction in serum IGF-I levels at response to the combination therapy (60% reduction of baseline IGF-I levels).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942909
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In refractory prostate cancer, dehydroepiandrosterone sulfate decreased further at response to triptorelin plus dexamethasone and lanreotide.
In plain wordsIn refractory prostate cancer, dehydroepiandrosterone sulfate decreased further from baseline at response to the three-drug regimen.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseDehydroepiandrosterone sulfate
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Dehydroepiandrosterone sulfate levels, although already significantly suppressed at baseline, had an additional significant reduction (P < 0.02) at response to therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated whether the combination of triptorelin, a LHRH analog (LHRH-A), with dexamethasone and lanreotide, a somatostatin analog, can produce objective clinical responses in metastatic androgen ablation-refractory prostate cancer (stage D3) patients who have relapsed, after combined androgen bl…
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1173942910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.